Physician profile
William W Kessler
NPI 1083710842
$1,588.36
in general payments reported to CMS, 2019-2025
30 companies · $593 in 2025
The $593 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $42.95 · 2021: $56.92 · 2022: $129 · 2023: $153 · 2024: $471 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $174.54 | 2024-2025 | Enhertu, Lynparza |
| Janssen Biotech, INC. | $141.62 | 2019-2025 | Tremfya, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $132.90 | 2019-2025 | Keytruda, Keytruda Qlex |
| Genzyme Corporation | $99.57 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.85 | 2024-2025 | |
| Lilly USA, LLC | $90.01 | 2023-2025 | Verzenio, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $82.79 | 2023-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $71.57 | 2019-2022 | |
| Daiichi Sankyo INC. | $67.84 | 2024-2025 | Vanflyta, Injectafer, Enhertu |
| Pharmaessentia USA Corporation | $57.91 | 2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $54.72 | 2024-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Taiho Oncology, INC. | $49.41 | 2022-2024 | |
| Legend Biotech USA INC. | $49.41 | 2025 | Carvykti |
| Celgene Corporation | $49.25 | 2025 | Reblozyl |
| Eisai INC. | $45.62 | 2020-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $38.52 | 2021-2022 | |
| Abbvie INC. | $36.64 | 2024-2025 | |
| Amgen INC. | $33.27 | 2022 | |
| Incyte Corporation | $31.71 | 2024-2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $26.33 | 2019 | |
| Janssen Scientific Affairs, LLC | $19.93 | 2019 | |
| Astellas Pharma US INC | $18.53 | 2025 | Xtandi |
| Geron Corporation | $18.49 | 2025 | Rytelo |
| Exelixis INC. | $17.12 | 2024 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $16.12 | 2023 | Ultomiris |
| Global Blood Therapeutics, INC. | $15.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2021 | |
| Glaxosmithkline, LLC. | $12.88 | 2022 | |
| Recordati_rare_diseases_inc. | $12.78 | 2023 | Sylvant |
| Octapharma USA, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.